拉贝洛尔联合硝苯地平治疗妊娠期高血压临床观察  

Clinical Observation of Labetalol Combined with Nifedipine in the Treatment of Gestational Hypertension

作　　者：宁艳芳 王冬梅 NING Yanfang;WANG Dongmei(Non-Commissioned Officer School Affiliated Hospital of Army Medical University,Shijiazhuang,Hebei,China 050047)

机构地区：[1]中国人民解放军陆军军医大学士官学校附属医院,河北石家庄050047

出　　处：《中国药业》2024年第21期95-98,共4页China Pharmaceuticals

基　　金：河北省卫生健康委员会2022年度医学科学研究课题计划[20220242]。

摘　　要：目的探讨拉贝洛尔联合硝苯地平治疗妊娠期高血压(GH)的临床疗效,以及对患者高温需求蛋白4(HtrA4)、血管生成素样蛋白2(ANGPTL2)、可溶性Fms样酪氨酸激酶-1(sFIt-1)水平的影响。方法选取医院2021年7月至2023年6月收治的GH患者86例,按随机数字表法分为试验组和对照组,各43例。在常规治疗基础上,两组患者均予拉贝洛尔,试验组患者加用硝苯地平,两组患者均治疗4周。结果试验组的总有效率为95.35%,显著高于对照组的76.74%(P<0.05);治疗后,两组患者的24 h尿蛋白定量、收缩压、舒张压、胎儿脐血流指标(搏动指数、阻力指数、收缩末期最大血流速/舒张末期最小血流速)及血清HtrA4,ANGPTL2,sFIt-1水平均显著降低(P<0.05),且试验组均显著低于对照组(P<0.05);试验组患者的不良妊娠结局发生率为6.98%,显著低于对照组的23.26%(P<0.05);试验组和对照组的不良反应发生率相当(9.30%比6.98%,P>0.05)。结论拉贝洛尔联合硝苯地平治疗GH的临床疗效良好,可有效控制患者的血压,改善胎儿脐血流指标,降低血清HtrA4,ANGPTL2,sFIt-1水平,减少不良妊娠结局,且安全性良好。Objective To investigate the clinical efficacy of labetalol combined with nifedipine in the treatment of gestational hypertension(GH),and its effect on the levels of high-temperature requirement protein 4(HtrA4),angiopoietin-like protein 2(ANGPTL2),and soluble Fms like tyrosine kinase 1(sFIt-1) in patients.Methods A total of 86 GH patients admitted to the hospital from July 2021 to June 2023 were selected and divided into the experimental group and the control group by the random number table method,with 43 cases in each group.On the basis of conventional treatment,the patients in the two groups were treated with labetalol,and the patients in the experimental group were additionally treated with nifedipine.Both groups were treated for four weeks.Results The total effective rate in the experimental group was 95.35%,which was significantly higher than76.74% in the control group(P < 0.05).After treatment,the 24 h urinary protein quantification,systolic blood pressure,diastolic blood pressure,fetal umbilical blood flow indicators(pulsatility index,resistance index,maximum end-systolic blood flow velocity/minimum end-diastolic blood flow velocity),and serum HtrA4,ANGPTL2,sFIT-1 levels in the two groups significantly decreased(P < 0.05),and those in the experimental group were significantly lower than those in the control group(P < 0.05).The incidence of adverse pregnancy outcomes in the experimental group was 6.98%,which was significantly lower than 23.26% in the control group(P < 0.05).The incidence of adverse reactions in the experimental group and the control group was comparable(9.30% vs.6.98%,P > 0.05).Conclusion Labetalol combined with nifedipine in the treatment of GH has good clinical efficacy and safety,which can effectively control patients′ blood pressure,improve fetal umbilical blood flow indicators,and reduce serum HtrA4,ANGPTL2,sFIT-1 levels,and adverse pregnancy outcomes.

关 键 词：拉贝洛尔 硝苯地平 妊娠期高血压 高温需求蛋白4 血管生成素样蛋白2 可溶性Fms样酪氨酸激酶-1 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R972.4[医药卫生—药学]